Biogen’s Gilmore O’Neill Joins Sarepta as Chief Medical Officer

Gilmore O’Neill has been appointed chief medical officer of Sarepta Therapeutics. O’Neill comes to the Cambridge, MA, biotech company from Biogen (NASDAQ: [[ticker:BIIB]]), where he was most recently senior vice president for all of the company’s clinical development. Sarepta’s first drug, eteplirsen (Exondys 51) won FDA approval in 2016 as a treatment for Duchenne muscular dystrophy. The company’s drug pipeline includes preclinical and clinical-stage compounds for rare neuromuscular diseases.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.